Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response in the first patient treated with Bria-OTS, the company's novel immunotherapy for metastatic breast cancer. This development marks an encouraging advancement in the treatment of a disease with high unmet medical need.
The reported clinical response includes the complete resolution of a lung metastasis, with stable disease maintained in other areas. The patient, a 78-year-old woman with hormone receptor-positive, HER2-negative metastatic breast cancer, had previously failed several lines of therapy before receiving Bria-OTS in a Phase 1/2a dose escalation study. The resolution occurred after four injection cycles of the monotherapy.
Dr. Neal Chawla, Associate Director of Clinical Research at the Sarcoma Oncology Center and Principal Investigator for the Bria-OTS study, expressed optimism about the rapid and robust clinical activity observed, as well as the treatment's excellent tolerability. Dr. William V. Williams, President and CEO of BriaCell, highlighted the potential of Bria-OTS to lead to new and effective treatments for metastatic breast cancer.
The Phase 1/2a clinical trial is evaluating the safety and efficacy of Bria-OTS as both a monotherapy and in combination with an immune checkpoint inhibitor. The trial design includes a dose escalation phase followed by an expansion phase that will assess combination therapy.
BriaCell Therapeutics Corp. is focused on developing novel immunotherapies aimed at transforming cancer care. With this latest clinical outcome, the company is taking a significant step toward advancing its innovative technology platform and expanding treatment options for patients with metastatic breast cancer and potentially other types of cancer in the future.
While the news of the clinical response has spurred investor confidence, resulting in the stock's ascent, it is important to note that the trial is still in its early stages, and further results will be necessary to confirm the efficacy and safety of Bria-OTS.
